Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1995 1
2000 1
2006 3
2007 4
2008 1
2009 14
2010 68
2011 3
2012 3
2013 2
2014 1
2015 4
2016 3
2017 1
2020 0
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 20133481

97 results
Results by year
Filters applied: . Clear all
Page 1
Of mice and men: therapeutic mTOR inhibition in polycystic kidney disease.
Pei Y. Pei Y. J Am Soc Nephrol. 2010 Mar;21(3):390-1. doi: 10.1681/ASN.2010010072. Epub 2010 Feb 4. J Am Soc Nephrol. 2010. PMID: 20133481 Free PMC article. No abstract available.
Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.
Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q, Wallace DP, Weimbs T, Wüthrich RP. Torres VE, et al. Clin J Am Soc Nephrol. 2010 Jul;5(7):1312-29. doi: 10.2215/CJN.01360210. Epub 2010 May 24. Clin J Am Soc Nephrol. 2010. PMID: 20498248 Free PMC article. Review.
mTOR inhibitors in polycystic kidney disease.
Watnick T, Germino GG. Watnick T, et al. N Engl J Med. 2010 Aug 26;363(9):879-81. doi: 10.1056/NEJMe1006925. Epub 2010 Jun 26. N Engl J Med. 2010. PMID: 20581393 No abstract available.
mTOR and cancer: many loops in one pathway.
Efeyan A, Sabatini DM. Efeyan A, et al. Curr Opin Cell Biol. 2010 Apr;22(2):169-76. doi: 10.1016/ Epub 2009 Nov 27. Curr Opin Cell Biol. 2010. PMID: 19945836 Free PMC article.
[mTOR and non-small cell lung cancer].
Wang L, Xu S, Yue W. Wang L, et al. Zhongguo Fei Ai Za Zhi. 2010 Jan;13(1):69-72. doi: 10.3779/j.issn.1009-3419.2010.01.13. Zhongguo Fei Ai Za Zhi. 2010. PMID: 20672708 Free PMC article. Review. Chinese. No abstract available.
Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP. Serra AL, et al. N Engl J Med. 2010 Aug 26;363(9):820-9. doi: 10.1056/NEJMoa0907419. Epub 2010 Jun 26. N Engl J Med. 2010. PMID: 20581391 Free article. Clinical Trial.
Functional consequences of mTOR inhibition.
Sudarsanam S, Johnson DE. Sudarsanam S, et al. Curr Opin Drug Discov Devel. 2010 Jan;13(1):31-40. Curr Opin Drug Discov Devel. 2010. PMID: 20047144 Review.
Small-molecule inhibitors: bULKing up mTOR inhibition.
Goodwin JM, Murphy LO. Goodwin JM, et al. Nat Chem Biol. 2015 Oct;11(10):758-60. doi: 10.1038/nchembio.1909. Nat Chem Biol. 2015. PMID: 26379023 No abstract available.
Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies.
Chapuis N, Tamburini J, Green AS, Willems L, Bardet V, Park S, Lacombe C, Mayeux P, Bouscary D. Chapuis N, et al. Leukemia. 2010 Oct;24(10):1686-99. doi: 10.1038/leu.2010.170. Epub 2010 Aug 12. Leukemia. 2010. PMID: 20703258 Free article. Review.
Rapamycin: the cure for all that ails.
Hasty P. Hasty P. J Mol Cell Biol. 2010 Feb;2(1):17-9. doi: 10.1093/jmcb/mjp033. Epub 2009 Oct 4. J Mol Cell Biol. 2010. PMID: 19805415
97 results
Jump to page